390 related articles for article (PubMed ID: 32665962)
1. The Two Faces of ACE2: The Role of ACE2 Receptor and Its Polymorphisms in Hypertension and COVID-19.
Bosso M; Thanaraj TA; Abu-Farha M; Alanbaei M; Abubaker J; Al-Mulla F
Mol Ther Methods Clin Dev; 2020 Sep; 18():321-327. PubMed ID: 32665962
[TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 and the Angiotensin-Converting Enzyme 2 Receptor: Angiotensin-Converting Enzyme Inhibitor/Angiotensin 2 Receptor Blocker Utilization and a Shift Towards the Renin-Angiotensin-Aldosterone System Classical Pathway.
Felber R; New W; Riskin SI
Cureus; 2024 Mar; 16(3):e55563. PubMed ID: 38576704
[TBL] [Abstract][Full Text] [Related]
3. Role and mechanism of angiotensin-converting enzyme 2 in acute lung injury in coronavirus disease 2019.
Liu MY; Zheng B; Zhang Y; Li JP
Chronic Dis Transl Med; 2020 Jun; 6(2):98-105. PubMed ID: 32550040
[TBL] [Abstract][Full Text] [Related]
4. Interactions of coronaviruses with ACE2, angiotensin II, and RAS inhibitors-lessons from available evidence and insights into COVID-19.
Kai H; Kai M
Hypertens Res; 2020 Jul; 43(7):648-654. PubMed ID: 32341442
[TBL] [Abstract][Full Text] [Related]
5. Renin-angiotensin-aldosterone system and COVID-19 infection.
Alexandre J; Cracowski JL; Richard V; Bouhanick B;
Ann Endocrinol (Paris); 2020 Jun; 81(2-3):63-67. PubMed ID: 32370986
[TBL] [Abstract][Full Text] [Related]
6. Effect of Angiotensin-Converting-Enzyme Inhibitor and Angiotensin II Receptor Antagonist Treatment on ACE2 Expression and SARS-CoV-2 Replication in Primary Airway Epithelial Cells.
Okoloko O; Vanderwall ER; Rich LM; White MP; Reeves SR; Harrington WE; Barrow KA; Debley JS
Front Pharmacol; 2021; 12():765951. PubMed ID: 34867390
[No Abstract] [Full Text] [Related]
7. Drugs acting on renin angiotensin system and use in ill patients with COVID-19.
Alexandre J; Cracowski JL; Richard V; Bouhanick B;
Therapie; 2020; 75(4):319-325. PubMed ID: 32553503
[TBL] [Abstract][Full Text] [Related]
8. Angiotensin-Converting-Enzyme 2 and Renin-Angiotensin System Inhibitors in COVID-19: An Update.
Shukla AK; Banerjee M
High Blood Press Cardiovasc Prev; 2021 Mar; 28(2):129-139. PubMed ID: 33635533
[TBL] [Abstract][Full Text] [Related]
9. Hypertension and COVID-19: Current Evidence and Perspectives.
Gallo G; Calvez V; Savoia C
High Blood Press Cardiovasc Prev; 2022 Mar; 29(2):115-123. PubMed ID: 35184271
[TBL] [Abstract][Full Text] [Related]
10. The Renin-Angiotensin System, Hypertension, and SARS-CoV-2 Infection: a Review.
Gathiram P; Mackraj I; Moodley J
Curr Hypertens Rep; 2021 Mar; 23(4):17. PubMed ID: 33768439
[TBL] [Abstract][Full Text] [Related]
11. Therapy with RAS inhibitors during the COVID-19 pandemic.
Spaccarotella C; Mazzitelli M; Migliarino S; Curcio A; De Rosa S; Torti C; Indolfi C
J Cardiovasc Med (Hagerstown); 2021 May; 22(5):329-334. PubMed ID: 33795584
[TBL] [Abstract][Full Text] [Related]
12. Angiotensin-converting enzyme inhibitor/angiotensin II receptor blocker treatment and haemodynamic factors are associated with increased cardiac mRNA expression of angiotensin-converting enzyme 2 in patients with cardiovascular disease.
Lebek S; Tafelmeier M; Messmann R; Provaznik Z; Schmid C; Maier LS; Birner C; Arzt M; Wagner S
Eur J Heart Fail; 2020 Dec; 22(12):2248-2257. PubMed ID: 33017071
[TBL] [Abstract][Full Text] [Related]
13. Renin-angiotensin system inhibition in COVID-19 patients.
de Vries AAF
Neth Heart J; 2020 Jul; 28(7-8):396-405. PubMed ID: 32514935
[TBL] [Abstract][Full Text] [Related]
14. Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality.
Fosbøl EL; Butt JH; Østergaard L; Andersson C; Selmer C; Kragholm K; Schou M; Phelps M; Gislason GH; Gerds TA; Torp-Pedersen C; Køber L
JAMA; 2020 Jul; 324(2):168-177. PubMed ID: 32558877
[TBL] [Abstract][Full Text] [Related]
15. Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers During the COVID-19 Pandemic: A Modeling Analysis.
Sadria M; Layton AT
PLoS Comput Biol; 2020 Oct; 16(10):e1008235. PubMed ID: 33031368
[TBL] [Abstract][Full Text] [Related]
16. Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB.
Rico-Mesa JS; White A; Anderson AS
Curr Cardiol Rep; 2020 Apr; 22(5):31. PubMed ID: 32291526
[TBL] [Abstract][Full Text] [Related]
17. Potential Implications of Angiotensin-converting Enzyme 2 Blockades on Neuroinflammation in SARS-CoV-2 Infection.
Paul D; Mohankumar SK; Thomas RS; Kheng CB; Basavan D
Curr Drug Targets; 2022; 23(4):364-372. PubMed ID: 34732115
[TBL] [Abstract][Full Text] [Related]
18. Effects of SARS-CoV-2 on Cardiovascular System: The Dual Role of Angiotensin-Converting Enzyme 2 (ACE2) as the Virus Receptor and Homeostasis Regulator-Review.
Aleksova A; Gagno G; Sinagra G; Beltrami AP; Janjusevic M; Ippolito G; Zumla A; Fluca AL; Ferro F
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33926110
[TBL] [Abstract][Full Text] [Related]
19. Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)--The BRACE CORONA Trial.
Lopes RD; Macedo AVS; de Barros E Silva PGM; Moll-Bernardes RJ; Feldman A; D'Andréa Saba Arruda G; de Souza AS; de Albuquerque DC; Mazza L; Santos MF; Salvador NZ; Gibson CM; Granger CB; Alexander JH; de Souza OF;
Am Heart J; 2020 Aug; 226():49-59. PubMed ID: 32502882
[TBL] [Abstract][Full Text] [Related]
20. RAAS Blockade and COVID-19: Mechanistic Modeling of Mas and AT1 Receptor Occupancy as Indicators of Pro-Inflammatory and Anti-Inflammatory Balance.
Melissa Hallow K; Dave I
Clin Pharmacol Ther; 2021 Apr; 109(4):1092-1103. PubMed ID: 33506503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
